Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 76% of modeled bridge. Strengths: Occupancy Rate, Revenue per Bed. Risks: Bed Count. Risk-adjusted uplift: $26.4M (vs $34.8M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $13.2M | $13.2M | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $12.7M | $363K | $13.1M | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $2.0M | $6.0M | $8.0M | $25.3M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $423K | $423K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 34.7% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $3.3M | $6.6M | $9.9M | $13.2M | $13.2M | $13.2M | $13.2M |
| Denial Rate Reduction | $0 | $3.3M | $6.5M | $9.8M | $13.1M | $13.1M | $13.1M | $13.1M |
| A/R Days Reduction | $0 | $2.7M | $5.4M | $8.0M | $8.0M | $8.0M | $8.0M | $8.0M |
| Clean Claim Rate | $0 | $211K | $423K | $423K | $423K | $423K | $423K | $423K |
| Cumulative | $0 | $9.5M | $18.9M | $28.2M | $34.8M | $34.8M | $34.8M | $34.8M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $34.8M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 51% / 7.9x | 56% / 9.1x | 60% / 10.4x | 61% / 11.0x | 63% / 11.6x |
| 9.0x | 46% / 6.7x | 51% / 7.8x | 55% / 8.8x | 57% / 9.4x | 58% / 9.9x |
| 10.0x | 41% / 5.7x | 46% / 6.7x | 50% / 7.6x | 52% / 8.1x | 54% / 8.6x |
| 11.0x | 37% / 4.8x | 42% / 5.8x | 46% / 6.7x | 48% / 7.1x | 50% / 7.5x |
| 12.0x | 33% / 4.2x | 38% / 5.0x | 42% / 5.8x | 44% / 6.2x | 46% / 6.7x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 4% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 6.2x, adding 2.3 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $95.8M | — | $95.8M | 14.5% |
| Year 1 | $98.7M | +$23.2M | $121.9M | 18.4% |
| Year 2 | $101.6M | +$34.8M | $136.4M | 20.6% |
| Year 3 | $104.7M | +$34.8M | $139.5M | 21.1% |
| Year 4 | $107.8M | +$34.8M | $142.6M | 21.6% |
| Year 5 | $111.1M | +$34.8M | $145.8M | 22.1% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $6.6M | $9.9M | $13.2M | $15.9M |
| Denial Rate Reductio | $6.5M | $9.8M | $13.1M | $15.7M |
| A/R Days Reduction | $4.0M | $6.0M | $8.0M | $9.6M |
| Clean Claim Rate | $211K | $317K | $423K | $507K |
| Total | $17.4M | $26.1M | $34.8M | $41.7M |
Peer Context — Where This Hospital Sits
Key metrics vs 9 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 14.5% | -4.4% | -0.5% | 11.6% | P75 |
| Net-to-Gross | 40.1% | 29.1% | 30.2% | 35.6% | P75 |
| Occupancy | 88.3% | 69.8% | 80.6% | 83.4% | P78 |
| Rev/Bed | $3.1M | $1.7M | $2.1M | $2.8M | P75 |
| Exp/Bed | $2.6M | $1.1M | $1.9M | $2.6M | P67 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.